Skip to content

Our Office +972-8-9301-015 |office@biokine.com

Search for:

Home
About Biokine
Pipeline
- clinical
- Pre-clinical
News & Events
Partnering
- Investors
Contact

Search for:

Home
About Biokine
Pipeline
- clinical
- Pre-clinical
News & Events
Partnering
- Investors
Contact

Search for:

BioLineRx Reports Second Quarter 2013 Results

Home/BioLineRx Reports Second Quarter 2013 Results

BioLineRx Reports Second Quarter 2013 Results

אמיר כספי2021-04-25T08:04:57+00:00August 6th, 2013|Uncategorized|

Search for:

Recent Posts

Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization.
BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine.
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
Bio BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe.

Recent Comments

Archives

Categories

No categories

Meta

Log in
Entries feed
Comments feed
WordPress.org

Popular
Recent
Comments

BioLineRx In-Licenses a Novel, Phase II Ready Drug for the Treatment of Leukemia and Other Hematological Cancers
September 4th, 2012
BioLineRx Announces BKT-140/BL-8040, for the Treatment of Leukemia and Other Types of Hematological Cancer, to be Presented at 2012 ASH Annual Meeting
November 7th, 2012
BioLineRx Enrolls First Patient in Phase 2 Clinical Trial
June 6th, 2013

Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
December 16th, 2020
BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization.
October 30th, 2020
BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine.
May 27th, 2020
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
February 27th, 2020
Bio BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe.
January 14th, 2020
Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE
December 13th, 2019
BioLineRx Presents Preclinical Data From Triple Combination of BL-8040
November 5th, 2019
BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients
March 27th, 2019
BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications
October 3rd, 2018
BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
August 7th, 2018
BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer
July 30th, 2018
BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation
May 17th, 2018
BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia
May 16th, 2018
BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells
January 23rd, 2018
BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients
December 21st, 2017
BioLineRx Reports Overall Survival Results from Long-Term Follow-Up of Phase 2a Trial in r/r AML
December 4th, 2017
BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer under Immunotherapy Collaboration
July 10th, 2017
BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination with Atezolizumab for Solid Tumors
June 1st, 2017
BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
March 20th, 2017
BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA
March 3rd, 2017

No comments have been published yet.

Our Company Mission

Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

The Avada Philosophy

Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

The Avada Promise

Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

We Can Deliver On Projects

Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

Recent Works

Recent Posts

Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization.
BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine.
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
Bio BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe.

Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consec tetur, adipisci velit, sed quia non numquam eius modi tempora voluptas amets unser.

John Doe, My Company

Aliquam erat volutpat. Quisque at est id ligula facilisis laoreet eget pulvinar nibh. Suspendisse at ultrices dui. Curabitur ac felis arcu sadips ipsums fugiats nemis.

Luke Beck, Theme Fusion

Contact Info

12345 north Street
New York City, NY 555555

Phone: 555-555-5555

Fax: 555-555-5555

Email: info@yourwebsite.com

Web: Yourwebsite.com

Popular
Recent
Comments

BioLineRx In-Licenses a Novel, Phase II Ready Drug for the Treatment of Leukemia and Other Hematological Cancers
September 4th, 2012
BioLineRx Announces BKT-140/BL-8040, for the Treatment of Leukemia and Other Types of Hematological Cancer, to be Presented at 2012 ASH Annual Meeting
November 7th, 2012
BioLineRx Enrolls First Patient in Phase 2 Clinical Trial
June 6th, 2013

Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
December 16th, 2020
BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization.
October 30th, 2020
BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine.
May 27th, 2020
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
February 27th, 2020
Bio BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe.
January 14th, 2020
Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE
December 13th, 2019
BioLineRx Presents Preclinical Data From Triple Combination of BL-8040
November 5th, 2019
BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients
March 27th, 2019
BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications
October 3rd, 2018
BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
August 7th, 2018
BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer
July 30th, 2018
BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation
May 17th, 2018
BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia
May 16th, 2018
BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells
January 23rd, 2018
BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients
December 21st, 2017
BioLineRx Reports Overall Survival Results from Long-Term Follow-Up of Phase 2a Trial in r/r AML
December 4th, 2017
BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer under Immunotherapy Collaboration
July 10th, 2017
BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination with Atezolizumab for Solid Tumors
June 1st, 2017
BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
March 20th, 2017
BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA
March 3rd, 2017

No comments have been published yet.

Our Company Mission

Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

The Avada Philosophy

Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

The Avada Promise

Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

We Can Deliver On Projects

Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

Recent Works

Recent Posts

Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization.
BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine.
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
Bio BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe.

Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consec tetur, adipisci velit, sed quia non numquam eius modi tempora voluptas amets unser.

John Doe, My Company

Aliquam erat volutpat. Quisque at est id ligula facilisis laoreet eget pulvinar nibh. Suspendisse at ultrices dui. Curabitur ac felis arcu sadips ipsums fugiats nemis.

Luke Beck, Theme Fusion

Contact Info

12345 north Street
New York City, NY 555555

Phone: 555-555-5555

Fax: 555-555-5555

Email: info@yourwebsite.com

Web: Yourwebsite.com

Copyright © 2020 Biokine LTD | All Rights Reserved |
Site By: Psik Advertising